arti-cell forte
boehringer ingelheim vetmedica gmbh - chondrogenic põhjustatud hobuste allogeense perifeerse vere-tuletatud mesenchymal tüvirakkude - muud lihas-skeleti süsteemi häirete ravimid - hobused - vähendada kerge kuni mõõduka korduva lonkamine seotud mitte-septiline liigesepõletik hobused.
bleo-cell süstelahuse pulber
cell pharm gmbh - bleomütsiin - süstelahuse pulber - 15000rÜ 10tk
enterisol ileitis suukaudse suspensiooni lüofilisaat ja lahusti
boehringer ingelheim vetmedica gmbh - lawsonia intracellularis, elus - suukaudse suspensiooni lüofilisaat ja lahusti - 1annus 50annus 1tk; 1annus 100annus 1tk; 1annus 10annus 1tk
porcilis lawsonia süsteemulsiooni lüofilisaat ja lahusti
intervet international b.v. - lawsonia intracellularis, inaktiveeritud - süsteemulsiooni lüofilisaat ja lahusti - 1annus 2ml 200ml 1tk; 1annus 2ml 100ml 1tk
porcilis lawsonia id süsteemulsiooni lüofilisaat ja lahusti
intervet international b.v. - lawsonia intracellularis, inaktiveeritud - süsteemulsiooni lüofilisaat ja lahusti - 1annus 0.2ml 50annus 10tk; 1annus 0.2ml 100annus 1tk; 1annus 0.2ml 50annus 1tk; 1annus 0.2ml 100annus 10tk
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastilised ained - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastilised ained - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - muud antineoplastilised ained - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
jaypirca
eli lilly nederland b.v. - pirtobrutinib - lümfoom, mantle-cell - protein kinase inhibiitorid - treatment of mantle cell lymphoma (mcl).
shingrix
glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vaktsiinid - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. kasutada shingrix peab olema kooskõlas ametlike soovitustega.